NCT05732207 Cerebellar Involvement in Alcohol Use Disorder (AUD)
| NCT ID | NCT05732207 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Alcohol Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 122 participants |
| Start Date | 2023-10-12 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 122 participants in total. It began in 2023-10-12 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational and interventional study is to better understand the involvement of the cerebellum in the brain reward system in persons with alcohol use disorder (AUD). The main questions it aims to answer are: 1. What is the nature of cerebellar input to the ventral tegmental area (VTA) in the brain reward system, and how is it perturbed in AUD? 2. What is the relationship between measures of cerebellar integrity and magnitude of reward activation to alcohol-related cues in cerebellar, VTA and other brain reward structures? 3. What is the therapeutic potential of cerebellar transcranial direct current stimulation (tDCS) for modulating alcohol cue reactivity, associated alcohol craving, and cerebellar - VTA functional connectivity in the brain reward system? Persons with AUD will be compared with healthy control participants.
Eligibility Criteria
Inclusion Criteria: * completed at least 8 years of education Exclusion Criteria: * Estimated Intelligence Quotient (IQ) \< 90 * less than 5th grade reading level * Left handed * Non-fluent in English * current drug use disorder other than alcohol (except nicotine and caffeine) and or recent drug use in the last 90 days * Positive breath alcohol level at time of MRI scan or discrepancies between alcohol biomarker and self-report that cannot be resolved * Exhibiting symptoms of alcohol withdrawal on visit 1 assessment * Significant current psychiatric distress and or treatment * History of any central nervous system disorder, presence of a seizure disorder, or use of anticonvulsant medication in the past 3 months * any serious medical condition detected on assessment or by medical record review; or have liver function tests more than three times normal at screening * History of metal implantation that would preclude MRI scanning; or other implants, pumps, pacemakers that would be contraindications for MRI scanning * Abnormal MRI scan or history of significant closed head trauma * Evidence of dementia * For women, pregnancy
Contact & Investigator
John E Desmond, PhD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT05732207 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 55 Years, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05732207 currently recruiting?
Yes, NCT05732207 is actively recruiting participants. Contact the research team at jdesmon2@jhmi.edu for enrollment information.
Where is the NCT05732207 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT05732207 clinical trial?
NCT05732207 is sponsored by Johns Hopkins University. The principal investigator is John E Desmond, PhD at Johns Hopkins University. The trial plans to enroll 122 participants.